Jaguar health, inc. (JAGX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Revenue
Product revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

141

167

195

234

258

0

0

0

Total revenue

5,054

5,775

5,864

6,023

5,201

4,416

4,362

4,330

4,343

4,361

0

0

0

-

0

0

-

-

-

-

-

Operating expenses
Cost of product revenue

3,626

3,815

4,029

3,818

3,166

2,765

2,442

1,911

1,328

880

262

65

49

51

72

99

107

123

0

0

0

Research and development

5,980

5,819

5,736

5,910

5,817

5,154

5,079

4,449

3,771

4,269

4,568

5,683

6,710

7,206

7,734

7,006

6,804

6,475

0

0

0

Sales and marketing

6,840

6,936

8,148

9,167

9,684

9,831

9,259

7,206

4,673

3,083

1,074

547

443

485

601

630

739

765

0

0

0

General and administrative

13,137

13,502

13,332

12,929

12,792

12,277

11,497

11,864

10,942

11,247

10,175

8,220

7,498

5,983

5,874

6,150

6,034

5,339

0

0

0

Series B convertible preferred stock inducement expense

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Settlement of Tempesta Royalty License Agreement

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of goodwill

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Impairment of indefinite-lived intangible assets

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

35,881

34,723

35,031

35,294

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

-

-

-

-

-

-

-

-

39,842

38,608

19,728

14,516

14,702

13,727

14,282

13,886

13,685

12,703

0

0

0

Loss from operations

-30,827

-28,948

-35,234

-35,013

-31,470

-30,823

-39,394

-40,228

-35,499

-34,247

-16,879

-12,718

-13,776

-13,585

-14,114

-13,691

-13,451

-12,445

0

0

0

Interest expense

5,382

5,730

5,999

5,518

2,573

2,628

2,594

2,187

1,631

1,209

1,012

782

881

985

1,058

986

2,668

3,317

0

0

0

Other income (expense)

-7

80

42

23

24

315

424

399

384

88

-13

-0

5

-11

-14

-55

-45

-27

0

0

0

Change in fair value of financial instruments

-1,054

-1,009

-1,453

-637

-548

-331

59

-302

-884

-695

0

0

0

-

-

-

-

-

-

-

-

Gain on Valeant settlement

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

501

0

0

0

Loss on extinguishment of debt

-

-4,940

0

0

0

-

-

-

-

-477

0

0

0

-

-

-

-

-

-

-

-

Loss before income tax expense

0

-

0

-

0

-

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

Income tax expense

-

-

0

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Net loss

-38,171

-38,539

-45,234

-43,817

-34,753

-32,146

-39,699

-28,801

-22,949

-21,968

-5,437

-13,613

-15,464

-14,733

-15,187

-14,733

-16,338

-16,291

0

0

0

Deemed dividend

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

346

0

0

0

Net loss attributable to common shareholders

-44,838

-44,726

-47,371

-41,827

-33,758

-32,146

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) attributable to common shareholders

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-16,497

-16,637

0

0

0

Net income (loss) per share, basic

-

-

-

-

-

-

-

-

-

-

1.29

-

-

-

-0.30

-

-

-

-

-

-

Net income (loss) per share, diluted

-

-

-

-

-

-

-

-

-

-

1.11

-

-

-

-0.30

-

-

-

-

-

-

Basic:

-

-

-

-

-

-

-

-

-

-

3,695

-

-

-

11,264

-

-

-

-

-

-

Diluted:

-

-

-

-

-

-

-

-

-

-

4,480

-

-

-

11,264

-

-

-

-

-

-

Net loss per share, basic and diluted (in dollars per share)

-0.56

24.94

-2.00

-15.11

-16.84

-61.51

-37.77

-53.24

-0.75

-

-

-1.84

-0.33

-

-

-0.35

-0.43

0.09

-0.36

-1.00

-1.43

Weighted-average common shares outstanding, basic and diluted (in shares)

15,141

12,419

5,841

1,106

493

-8,117

162

162

8,631

-

-

979

14,157

-

-

10,314

9,307

8,204

8,123

5,410

2,874

Product revenue, net
Total revenue

5,054

5,775

5,864

6,023

5,201

4,238

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue
Total revenue

-

-

-

-

-

177

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of Series A convertible preferred
Deemed dividend

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series B convertible preferred stock
Deemed dividend

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series 1 warrants
Deemed dividend

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-